OBJECTIVE: Inflammation plays an integral role in the development of abdominal aortic aneurysms (AAAs), and the expression of cyclooxygenase (COX)-2 is increased in aneurysmal tissue compared with normal aorta. Nonsteroidal anti-inflammatory drugs, which inhibit the activity of COX-1 and COX-2, decrease AAA expansion in humans and animal models of the disease. In the current study, we investigated the effectiveness of selective inhibition of COX-1 or COX-2 in attenuating AAA formation. METHODS AND RESULTS: Eight-week-old male apolipoprotein E-deficient mice were treated with selective inhibitors of COX-1 or COX-2, SC-560 (approximately 25 mg.kg(-1).day(-1)), or celecoxib (approximately 125 mg.kg(-1).day(-1)), respectively. COX inhibitors were administered 1 week before angiotensin II (Ang II; 1000 ng.kg(-1).min(-1)) or saline infusion and throughout the time course of the experiment. COX-1 inhibition had no effect on incidence (control: 90% [9:10] versus SC-560: 89% [8:9]) or severity of Ang II-induced AAA formation. In contrast, celecoxib decreased the incidence (control: 74% [22:30] versus celecoxib: 11% [2:19]; P<0.001) and severity (P=0.001) of AAA formation. Celecoxib also decreased the incidence and severity of AAAs in nonhyperlipidemic mice. CONCLUSIONS: COX-2-derived prostanoids play a fundamental role in the development of Ang II-induced AAAs in both hyperlipidemic and nonhyperlipidemic mice.
OBJECTIVE: Inflammation plays an integral role in the development of abdominal aortic aneurysms (AAAs), and the expression of cyclooxygenase (COX)-2 is increased in aneurysmal tissue compared with normal aorta. Nonsteroidal anti-inflammatory drugs, which inhibit the activity of COX-1 and COX-2, decrease AAA expansion in humans and animal models of the disease. In the current study, we investigated the effectiveness of selective inhibition of COX-1 or COX-2 in attenuating AAA formation. METHODS AND RESULTS: Eight-week-old male apolipoprotein E-deficientmice were treated with selective inhibitors of COX-1 or COX-2, SC-560 (approximately 25 mg.kg(-1).day(-1)), or celecoxib (approximately 125 mg.kg(-1).day(-1)), respectively. COX inhibitors were administered 1 week before angiotensin II (Ang II; 1000 ng.kg(-1).min(-1)) or saline infusion and throughout the time course of the experiment. COX-1 inhibition had no effect on incidence (control: 90% [9:10] versus SC-560: 89% [8:9]) or severity of Ang II-induced AAA formation. In contrast, celecoxib decreased the incidence (control: 74% [22:30] versus celecoxib: 11% [2:19]; P<0.001) and severity (P=0.001) of AAA formation. Celecoxib also decreased the incidence and severity of AAAs in nonhyperlipidemic mice. CONCLUSIONS:COX-2-derived prostanoids play a fundamental role in the development of Ang II-induced AAAs in both hyperlipidemic and nonhyperlipidemic mice.
Authors: Frank M Davis; Debra L Rateri; Anju Balakrishnan; Deborah A Howatt; Dudley K Strickland; Selen C Muratoglu; Christopher M Haggerty; Brandon K Fornwalt; Lisa A Cassis; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2014-11-13 Impact factor: 8.311
Authors: Wen-Liang Song; Jane Stubbe; Emanuela Ricciotti; Naji Alamuddin; Salam Ibrahim; Irene Crichton; Maxwell Prempeh; John A Lawson; Robert L Wilensky; Lars Melholt Rasmussen; Ellen Puré; Garret A FitzGerald Journal: J Clin Invest Date: 2012-03-12 Impact factor: 14.808
Authors: T Aoki; M Nishimura; T Matsuoka; K Yamamoto; T Furuyashiki; H Kataoka; S Kitaoka; R Ishibashi; A Ishibazawa; S Miyamoto; R Morishita; J Ando; N Hashimoto; K Nozaki; S Narumiya Journal: Br J Pharmacol Date: 2011-07 Impact factor: 8.739
Authors: Jing Liu; Hong Lu; Deborah A Howatt; Anju Balakrishnan; Jessica J Moorleghen; Mary Sorci-Thomas; Lisa A Cassis; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2015-06-04 Impact factor: 8.311
Authors: Darshini B Trivedi; Charles D Loftin; James Clark; Page Myers; Laura M DeGraff; Jennifer Cheng; Darryl C Zeldin; Robert Langenbach Journal: Circ Res Date: 2013-03-22 Impact factor: 17.367